http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Characterization of wheat bran oil obtained by supercritical carbon dioxide and hexane extraction
Go-Woon Jung,Hee-Moon Kang,전병수 한국공업화학회 2012 Journal of Industrial and Engineering Chemistry Vol.18 No.1
Supercritical carbon dioxide (SC-CO2) and soxhlet extraction using was carried out to extract oil from wheat bran oil. For SC-CO2, the pressure and temperature were ranging from 10 to 30 MPa and 313.15–333.15 K. The extraction was performed in a semi batch process with a CO2 flow rate of 26.81 g/min for 2 h. Wheat bran oil was characterized to investigate the quality. Acid value (AV) and peroxide value (POV)were higher in hexane extracted oil compared to SC-CO2 extracted oil. Induction period was measured by rancimat test. The oil obtained by SC-CO2 extraction had higher capability to delay the oxidation by surrounding environment. The DPPH radical scavenging activity was also measured. The SC-CO2extracted oil showed higher radical scavenging activity compared to hexane extracted oil.
( Go Woon Choi ),( Nam Ju Lim ),( Jung U Shin ),( Hee Jung Lee ),( Moon Soo Yoon ),( Dong Hyun Kim ) 대한피부과학회 2020 대한피부과학회 학술발표대회집 Vol.72 No.1
Background: Psoriasis can be treated successfully with biologics in a fixed dosing interval. However, there are limited data on the treatment outcomes of biologics with irregular dosing interval in psoriasis. Objectives: This study aimed to compare treatment outcomes of biologics with regular and irregular dosing interval in psoriasis. Methods: This was a retrospective single-center study. Patients diagnosed with plaque psoriasis who were treated with biologics between 1 January 2014 and 31 December 2019 were included. We compared the demographics, treatment regimen, and treatment outcomes for each regular and irregular dosing interval group. Results: Among 95 patients, 63 (66.3%) patients were treated with biologics with regular dosing interval, and 32 (33.7%) with irregular dosing interval. No significant difference regarding final Psoriasis Area Severity Index (PASI) (1.4 vs. 1.6; p=0.40) and percentage of PASI improvement from baseline (-89.6% vs. -90.7%; p=0.63) was found between two groups. The number of switching biologics was not significantly different but higher in irregular group than regular group (8 (12.7%) vs. 9 (28.1%); p=0.06). Conclusion: In this study, noninferiority was not demonstrated for irregular dosing interval of biologics based on the PASI in patients with psoriasis compared with regular dosing interval. However, irregular biologic dosing interval may increase the number of switching biologics.
Pembrolizumab에 의해 유발된 독성표피괴사용해 1예
최고운 ( Go Woon Choi ),이희정 ( Hee Jung Lee ),김동현 ( Dong Hyun Kim ),윤문수 ( Moon Soo Yoon ),신정우 ( Jung U Shin ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.2
Pembrolizumab is an immune checkpoint inhibitor that selectively blocks the programmed cell death (PD)-1 receptor. Although it has a dramatic effect on the treatment of advanced malignancies, instability of immune tolerance may cause immune-related adverse events in the skin. A 62-year-old male with a history of metastatic urothelial carcinoma was referred to the dermatology department and presented with a widespread mucocutaneous rash. Itching appeared 7 days after the first administration of pembrolizumab, and on the third day after the second administration, an erythematous maculopapular rash that coalesced into large flaccid bullae on the whole body with a positive Nikolsky’s sign developed. A biopsy revealed a subepidermal bulla with basal keratinocyte necrosis. Pembrolizumab was discontinued due to the diagnosis of toxic epidermal necrolysis (TEN), and intravenous methylprednisolone was started. Herein, we report a case of TEN induced by pembrolizumab to highlight immune-related cutaneous adverse events in patients receiving anti-PD-1 therapy. (Korean J Dermatol 2022;60(2): 120∼124)
건선에서 생물학적 제제의 규칙적 및 불규칙적 투여에 따른 치료 결과 비교
최고운 ( Go Woon Choi ),임남주 ( Nam Ju Lim ),신정우 ( Jung U Shin ),이희정 ( Hee Jung Lee ),윤문수 ( Moon Soo Yoon ),김동현 ( Dong Hyun Kim ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.6
Background: Patients with stable psoriasis showing clear/near-clear response can consider extending the dosing interval of biologics. However, few studies have reported the treatment outcomes following irregular dosing intervals of biologics in patients with psoriasis. Objective: We compared treatment outcomes after regular and irregular dosing intervals of biologics in patients with psoriasis. Methods: This single-center, retrospective observational study included patients who received biologics for treatment of plaque psoriasis between January 1, 2014 and December 31, 2019. We compared patient demographics, clinical characteristics, biologics administered, and treatment outcomes based on the regularity of the dosing interval. Results: Among 95 patients investigated, 63 (66.3%) received biologics at regular dosing intervals. We observed no significant intergroup differences in the final Psoriasis Area Severity Index (PASI) scores (1.2 vs. 1.8, p=0.16) and in the percentage improvement in PASI scores from baseline levels (-89.8% vs. -90.8%, p=0.68). The rate at which biologics were switched was higher in the irregular-dosing group than in the regular-dosing group; however, the difference was statistically nonsignificant (28.1% vs. 12.7%, p=0.06). We observed a significant intergroup difference in patients who were administered guselkumab at baseline (12 [21.8%] vs. 0 [0.0%], p=0.01). Conclusion: This study showed that compared with regular dosing intervals, irregular dosing intervals of biologics were associated with high rates of switching of these agents, although we observed no statistically significant differences with regard to PASI scores. Therefore, it is important to adhere to the standard dosing schedule prescribed for biologics, and guselkumab may improve patient compliance. (Korean J Dermatol 2021;59(6):440∼446)
Primary cutaneous adenoid cystic carcinoma of the chest wall
( Ji Hae An ),( Go Woon Choi ),( Seung Hui Seok ),( Seon Gu Lee ),( Jung U Shin ),( Hyun Jung Kim ),( Hee Jung Lee ),( Dong Hyun Kim ),( Moon Soo Yoon ) 대한피부과학회 2019 대한피부과학회 학술발표대회집 Vol.71 No.1
Adenoid cystic carcinoma (ACC) is a malignant neoplasm of glands which commonly occurs in salivary glands. Primary cutaneous adenoid cystic carcinoma (PCACC) is a rare form of ACC that primarily presents on the skin. A diagnosis of a primary tumor arising in the skin can be made only after excluding metastatic deposits from other, more common sites. PCACC tends to infiltrate and recur locally but rarely metastasizes to distant organs and lymph nodes. A 62-year-old female presented with a 1-year history of an asymptomatic erythematous indurated plaque on her anterior chest wall. Biopsy finding revealed an intradermal tumor without an overlying epidermal connection. The tumor was composed of islands of basaloid cells arranged in cribriform pattern with areas showing cystic degeneration. Cystic spaces contained abundant basophilic mucin. Perineural invasion was conspicuous. Immunohistochemical analysis revealed positivity for c-kit staining and epithelial membrane antigen (EMA) staining in focal luminal area. The lesion was diagnosed as ACC. Final diagnosis of PCACC was made after excluding the possibility of metastasis from other primary lesion by imaging studies. The patient has been followed up for 6 months with no evidence of recurrence of metastasis after total excision of the lesion. We herein report a case of PCACC of the chest wall to raise awareness of this rare tumor with review of literature.